Pfizer announced Tuesday that it discontinued a Phase III study of Sutent (sunitinib) as a first-line treatment for patients with metastatic colorectal cancer. The drugmaker said an independent data monitoring committee found that the addition of Sutent to FOLFIRI chemotherapy in the SUN 1122 trial “would be unable to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival compared to FOLFIRI alone.”

[ad]

No new safety issues were identified, Pfizer stated, noting that it will continue to study Sutent in late-stage trials as a potential treatment for other cancer types, including advanced forms of breast cancer, non-small-cell lung cancer, hepatocellular carcinoma and hormone-refractory prostate cancer.

The drug had global sales of $847 million last year.

Source: FirstWord

Popularity: 3% [?]